


Please type a plus sign (+) inside this box



App for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	10/001,407
Filing Date	October 22, 2001
First Named Inventor	YANG et al.
Group Art Unit	1648
Examiner Name	Parkin, J.
Attorney Docket Number	GP117-03.UT

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
X		BERKHOUT et al., "Secondary Structure of the HIV-2 Leader RNA Comprising the tRNA-Primer Binding Site", Nucleic Acids Res., Mar. 1993, 21(5):1171-1178	
		BERKHOUT et al., DATABASE GSN, Online, Jun. 1993, retrieved from EBI Database accession no. X72325	
		BUSH et al., "Detection of Human Immunodeficiency Virus Type 1 RNA in Plasma Samples from High-Risk Pediatric Patients by Using the Self-Sustained Sequence Replication Reaction", J Clin Microbiol., Feb. 1992, 30(2):281-286	
		DE BAAR et al., "Design and Evaluation of a Human Immunodeficiency Virus Type 1 RNA Assay Using Nucleic Acid Sequence-Based Amplification Technology Able to Quantify Both Group M and O Viruses by Using the Long Terminal Repeat as Target" J Clin Microbiol., Jun. 1999, 37(6):1813-1818.	
		EIKEN CHEM CO LTD., DATABASE GSN, Online, July 1998, retrieved from EBI Database accession no. AAV19509	
		KRAISELBURD, DATABASE GSN, Online, Jun. 1996, retrieved from EBI Database accession no. AAT06604	
		PIENIAZEK et al., "Identification of Mixed HIV-1/HIV-2 Infections in Brazil by Polymerase Chain Reaction", AIDS, Nov. 1991, 5(11):1293-1299	
↓		VAN GEMEN et al., "The One-Tube Quantitative HIV-1 RNA NASBA: Precision, Accuracy, and Application", PCR Methods Appl., Feb. 1995, 4(4):S177-S184	

Examiner  
Signature

Date  
Considered


11/2/01

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900  
FEB 14 2002

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/001,407
		Filing Date	October 22, 2001
		First Named Inventor	YANG et al.
		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
Sheet	1	of	4
		Attorney Docket Number	GP117-03.UT

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<div>↓</div>		4868105	A	Urdea et al.	09-19-1989	
		4965188	A	Mullis et al.	11-23-1990	
		5008182	A	Sninsky et al.	04-16-1991	
		5066782	A	Montagnier et al.	11-19-1991	
		5124246	A	Urdea et al.	06-23-1992	
		5130238	A	Malek et al.	07-14-1992	
		5176995	A	Sninsky et al.	01-05-1993	
		5223423	A	Franchini et al.	06-29-1993	
		5283174	A	Arnold, Jr. et al.	02-01-1994	
		5310651	A	Alizon et al.	05-10-1994	
		5399491	A	Kacian et al.	03-21-1995	
		5437990	A	Burg et al.	08-01-1995	
		5455166	A	Walker	10-03-1995	
		5470572	A	Kraiselburd	11-28-1995	
		5472840	A	Stefano	12-05-1995	
		5545726	A	Alizon et al.	08-13-1996	
		5554516	A	Kacian et al.	09-10-1996	
		5591578	A	Meade et al.	01-07-1997	
		5639604	A	Arnold, Jr. et al.	06-17-1997	
		5656207	A	Woodhead et al.	08-12-1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ts
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		EP	0239425	A1	Institut Pasteur	09-30-1997		*
		EP	0403333	B1	Institut Pasteur et al.	12-19-1990		**
		EP	0404625	B1	Institut Pasteur et al.	12-27-1990		**
		EP	0525882	A1	Akzo N.V.	02-03-1993		
		EP	0655501	A1	Qiagen GmbH et al.	05-31-1995		
		EP	0750041	A2	Institut Pasteur	12-27-1996		*
		EP	0806484	A2	Institut Pasteur et al.	11-12-1997		*
		EP	0887427	A2	Ortho-Clinical Diagnostics, Inc.	12-30-1998		
		EP	1026263	A2	Ortho-Clinical Diagnostics, Inc.	08-09-2000		
		WO	8801302	A1	Stake Diagnostics, Inc.	02-25-1988		

\* An English language abstract is included. \*\* An English language abstract and English language claims are included.

Examiner Signature	Date Considered
	11/12/99

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

FEB 12 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number 10/001,407  
Filing Date October 22, 2001  
First Named Inventor YANG et al.  
Group Art Unit To Be Assigned  
Examiner Name To Be Assigned  
Attorney Docket Number GP117-03.UT

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5658737	A	Nelson et al.	08-19-1997	
		5688637	A	Moncany et al.	11-18-1997	
		5712385	A	McDonough et al.	01-27-1998	
		5770369	A	Meade et al.	06-23-1998	
		5786208	A	Clark et al.	07-28-1998	
		5827935	A	Rossi et al.	10-27-1998	
		5840488	A	Hogan	11-24-1998	
		5840873	A	Nelson et al.	11-24-1998	
		5843654	A	Heisler et al.	12-01-1998	
		5843669	A	Kaiser et al.	12-01-1998	
		5856088	A	McDonough et al.	01-05-1999	
		5962665	A	Kroeger et al.	10-05-1999	
		5976814	A	Bard et al.	11-02-1999	
		5998172	A	Haynes et al.	12-07-1999	
		6001558	A	Backus et al.	12-14-1999	
		6020123	A	Sonigo et al.	02-01-2000	
		6096321	A	Girardeau et al.	08-01-2000	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	8810315	A1	Sika Diagnostics, Inc.	12-29-1988		
		WO	9322461	A1	Gen-Probe Incorporated	11-11-1993		
		WO	9403472	A1	Gen-Probe Incorporated	02-17-1994		
		WO	9414967	A2	Institut National de la Recherche Agronomique	07-07-1994		
		WO	9503430	A1	Gen-Probe Incorporated	02-02-1995		
		WO	9532305	A1	Dako A/S	11-30-1995		
		WO	9850583	A1	Gen-Probe Incorporated	11-12-1998		
		WO	9855640	A1	Oxford Biomedica (UK) Limited	12-10-1998		
		WO	0001850	A2	Gen-Probe Incorporated	01-13-2000		
		WO	0125419	A1	Cyto-Genix, Inc.	04-12-2001		


\* An English language abstract is included. \*\* An English language abstract and English language claims are included.

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


  
 are required to respond to a

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	<b>10/001,407</b>
<b>Filing Date</b>	<b>October 22, 2001</b>
<b>First Named Inventor</b>	<b>YANG et al.</b>
<b>Group Art Unit</b>	<b>To Be Assigned</b>
<b>Examiner Name</b>	<b>To Be Assigned</b>
<b>Attorney Docket Number</b>	<b>GP117-03.UT</b>

(use as many sheets as necessary)

Sheet 3 of 4 Attorn

Attorney Docket Number	GP117-03.UT
------------------------	-------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

\* An English language abstract is included. \*\* An English language abstract and English language claims are included.

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

FEB 12 2002

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/001,407
Filing Date	October 22, 2001
First Named Inventor	YANG et al.
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	GP117-03.UT

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
[Signature]		ABRAVAYA et al., "Performance of a Multiplex Qualitative PCR LCx Assay for Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Subtypes, Group O, and HIV-2", J. Clin. Microbiol., Feb. 2000, 38(2):716-23, American Society for Microbiology, US
[Signature]		DIAMOND et al., "Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA", J. Clin. Microbiol., March 1998, 36(3):809-811, American Society for Microbiology, US
[Signature]		REEVES et al., "Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo", J. Virol., Sept. 1999, 73(9):7795-804, American Society for Microbiology, US
[Signature]		WALTHER-JALLOW et al., "High Concordance between Polymerase Chain Reaction and Antibody Testing of Specimens from Individuals Dually Infected with HIV Types 1 and 2 in Guinea-Bissau, West Africa", AIDS Res. Hum. Retroviruses, July 1999, 15(11):957-62, Mary Ann Liebert Incorporated, US

Examiner  
Signature

Date

Considered

W/R/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.